IL-15 enhances functional properties and responses of CD28-negative CD4+ cytotoxic T cells expanded in Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disorder that results in an attack by bodys immune system of its own tissues, causing chronic inflammation and tissue damage. T cells play a key role in the pathogenesis of SLE, as they secrete pro-inflammatory cytokines as well as mediate direct effects on target tissues. Recently, CD4-positive T cells with cytotoxic potential were showed to be involved in autoimmune disease progression and tissue damage. However, whether this cell type expands and plays effector functions in SLE patients remain to be elucidated. Analyzing single-cell RNA sequencing (scRNA-Seq) data and flow cytometry data, we find that cytotoxic CD4+CD28- T cells are present in SLE patients. We also show that these cells expand most prominently in patients affected by lupus nephritis, and they exhibit cytotoxic activity against human renal glomerular endothelial cells in vitro. In addition, our study suggests that Interleukin-15 (IL-15) promotes the expansion, proliferation and cytotoxic function of CD4+CD28- T cells in SLE patients. Tofacitinib, a selective JAK3 inhibitor, inhibits the effect of IL-15 on CD4+CD28- T cells. Together, our study clearly demonstrated that CD4+ CD28- T cells characterized by proinflammatory properties and cytolytic function expand in SLE patients. The pathogenic potential of these CD4+ CD28- T cells is driven by IL-15/IL-15R/JAK3/STAT5 signaling pathway, which may open new avenues for therapeutic intervention to prevent progression of SLE patients.